



ASX, Nasdaq and Media Release  
12 December 2022

## **Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD**

**Melbourne, Australia; 12 December, 2022** – Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13<sup>th</sup> December 6:30pm – 7:30pm EST USA (Wednesday 14<sup>th</sup> December 10:30am – 11:30am AEDT).

Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea’s Phase 2b and Phase 3 clinical trial program followed by a Question and Answer session on the current management of wet AMD patients and the potential role of OPT-302 within the treatment landscape.

Participants are invited to submit questions via this [link](#) prior to the conference call. Please [click here to register](#) for the virtual meeting which will be held via Zoom.

### **About Opthea Limited**

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

### **Inherent risks of Investment in Biotechnology Companies**

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

**Authorized for release to ASX by Megan Baldwin, CEO & Managing Director**



**Company & Media Enquiries:**

**U.S.A. & International:**

Timothy E. Morris, CFO  
Opthea Limited  
Tel: +1 650-400-6874

**Australia:**

Rudi Michelson  
Monsoon Communications  
Tel: +61 (0) 3 9620 3333

**Media:**

Hershel Berry  
Blueprint Life Science Group  
Tel: +1 415 505 3749  
hberry@bplifescience.com

**Join our email database to receive program updates:**

Tel: +61 (0) 3 9826 0399 Email: [info@opthea.com](mailto:info@opthea.com) Web: [www.opthea.com](http://www.opthea.com)